Cytokinetics Stays the Course

Cytokinetics claims to have implemented a far more detailed long-term strategic plan than most biotechs. That plan will be put to the test as it enters the clinic with an acute CHF compound. Until now, the company has relied on a partner (GSK) to shoulder the burden of developing its drug candidates. Now it will have to do that heavy lifting, at least for a while, on its own.